The Latest Breaking News from Brian Abrahams

Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams. Berger said Gilead is focused on advancing Trodel

MarketBeat · May 24

Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline

RBC Capital Markets upgraded Neumora Therapeutics, Inc. (NASDAQ:NMRA) from Sector Perform to Outperform, with an increased price forecast from $4 to $7.

Benzinga · Dec 1, 2025

A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts

In the last three months, 19 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:VRTX), offering a diverse range of perspectives from bullish to bearish.

Benzinga · Dec 9, 2024